aaa February 2014 WELCOME TO THE CANADIAN CANCER CLINICAL TRIALS NETWORK 2nd Canadian Cancer Clinical Trials Network Stakeholder Meeting The Canadian Cancer Clinical Trials Network (3CTN) held its second stakeholder meeting on February 18, 2014 at the St. Andrew’s Club and Conference Centre in Toronto. Dr. Janet Dancey, Scientific Director, provided an update on Phase I activities and the progress of the 3CTN business plan to date. The meeting agenda focused on the elements that have changed since the first stakeholder meeting on November 2, 2013. Over 40 stakeholders attended the meeting and were invited to comment and provide feedback on new and updated business plan sections. Prior to the meeting, the draft business plan was sent to funders and the Steering Committee (SC) for review. The key changes highlighted at the meeting included updated 3CTN objectives, the creation of an Executive Committee and three strategic teams, the introduction of disease site committees and portfolio maps. The 3CTN working groups recommendations have been prioritized into Network initiatives approved by the SC and will be implemented in Phase II. The feedback from the meeting will be incorporated into the final business plan. Prior to submission, the business plan will be reviewed and approved by the SC. The 3CTN business plan will be submitted on March 14 for international review. For more information, contact Karen Arts. About 3CTN • • • • • • 3CTN is a pan-Canadian initiative with broad stakeholder engagement; The focus of 3CTN is supporting clinical trial activities at sites conducting academic trials; 3CTN will improve the efficiency and quality of clinical trials by providing coordination and support for a network of teams at cancer treatment centres and hospitals; 3CTN is currently in Phase I: development of a pan-Canadian business plan; In Phase II, 3CTN will implement the approved business plan. Visit www.3ctn.ca for more information. | February 2014 2 Progress to Date Second Steering Committee meeting held; Fifth Portfolio Committee meeting held and portfolio details finalized; 3CTN working group final recommendations completed; Program logic model and prioritization of Network initiatives completed. Draft of business plan completed and sent to funders and Steering Committee for feedback; Second 3CTN Stakeholder Meeting held on February 18, 2014; Meeting held with funders on Feb, 19, 2014. \\\\\\ Contact Us Question of the Month: How will the Network Cancer Centres (NCCs) work with the Network Affiliated Cancer Centres (NACCs)? In May 2014, 3CTN will release a Request for Applications (RFA) for Network Regional Coordinating Centres (NRCCs) and NCCs. In the application, the NCCs will need to describe their proposed NACC linkages, collaboration activities, budget and deliverables. The NCCNACC relationship will encourage collaboration and increase access to clinical trials for patients. 3CTN encourages potential NCCs to start discussions with their NACCs as soon as possible. More details to follow once the RFA has been released in early June. Implementation Strategy WANTED: Letters of Support As part of the Business Plan, 3CTN would like to include letters of support from as many stakeholder groups as possible. To show your support, submit a letter of support to Karen Arts. Sincere Thanks! MaRS Centre 661 University Ave Suite 510 Toronto, Ontario Canada M5G 0A3 Once 3CTN receives notification of the successful review of the business plan, initial implementation activities will include the following: Establish agreements with Funders; Issue RFA for NRCC, NCCs and hold RFA information sessions; Establish NCC baseline recruitment and trial activities; Identify NCC-NACC linkages; Finalize 3CTN governance committees and strategic teams. www.3ctn.ca 3CTN aims to finalize agreements with NRCCs and NCCs in September 2014. Stay tuned in May 2014 for an official announcement on the start of Phase II from 3CTN! For inquiries please contact: [email protected] or call 1-866-678-6427 Canadian Cancer Clinical Trials Network Key Dates March 14, 2014: 3CTN Business Plan submitted and Phase I ends As Phase I comes to an end, 3CTN would like to thank all stakeholders, advisors, Steering Committee, Portfolio Committee and working group members for their time, expertise and input into the development of the 3CTN business plan. Production of this newsletter has been made possible through financial support from the Canadian Partnership against Cancer and Health Canada. For a list of our partners, please visit www.3ctn.ca.
© Copyright 2017